Skip to content

Study · Non-randomized trial · 1989

3 results

Effect of intravenous glucagon and glucagon-(1-21)-peptide on motor activity of sphincter of Oddi in humans.

Ponce J, Garrigues V, Pertejo V, Sala T, Lazaro MJ, De Val A, Picazo J

Digestive diseases and sciences1 Jan 1989Cited by 8 (Europe PMC)

PMID2910681 (opens in a new tab)DOI10.1007/bf01536155 (opens in a new tab)PepBankPUB-02910681
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients undergoing ERCP and biliary manometry, glucagon produced a nonsignificant decrease in sphincter of Oddi basal pressure.

    In plain wordsIn patients undergoing bile duct tests, glucagon did not significantly lower the sphincter's resting pressure.

    Peptide
    Glucagon
    Outcome
    No significant changeSphincter of Oddi basal pressure
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon produced a nonsignificant decrease in basal pressure, but significantly reduced both frequency and amplitude of phasic activity of the sphincter of Oddi.
    1 context sentence
    Summary · context
    The effect of glucagon and glucagon-(1-21)-peptide on sphincter of Oddi motor activity was evaluated in 20 patients undergoing ERCP and endoscopic biliary manometry.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients undergoing ERCP and biliary manometry, glucagon significantly reduced sphincter of Oddi phasic activity frequency.

    In plain wordsIn patients undergoing bile duct tests, glucagon reduced how often the sphincter contracted.

    Peptide
    Glucagon
    Outcome
    DecreaseSphincter of Oddi phasic activity frequency
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon produced a nonsignificant decrease in basal pressure, but significantly reduced both frequency and amplitude of phasic activity of the sphincter of Oddi.
    1 context sentence
    Summary · context
    The effect of glucagon and glucagon-(1-21)-peptide on sphincter of Oddi motor activity was evaluated in 20 patients undergoing ERCP and endoscopic biliary manometry.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients undergoing ERCP and biliary manometry, glucagon significantly reduced sphincter of Oddi phasic activity amplitude.

    In plain wordsIn patients undergoing bile duct tests, glucagon reduced the strength of the sphincter's contractions.

    Peptide
    Glucagon
    Outcome
    DecreaseSphincter of Oddi phasic activity amplitude
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon produced a nonsignificant decrease in basal pressure, but significantly reduced both frequency and amplitude of phasic activity of the sphincter of Oddi.
    1 context sentence
    Summary · context
    The effect of glucagon and glucagon-(1-21)-peptide on sphincter of Oddi motor activity was evaluated in 20 patients undergoing ERCP and endoscopic biliary manometry.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.